Federal Register: December 22, 2006 (Volume 71, Number 246)

DOCID: FR Doc E6-21950

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Docket ID: [Docket No. 2006D-0172]

NOTICE: NOTICES

ACTION: Reports and guidance documents; availability, etc.:

DOCUMENT ACTION: Notice.

SUBJECT CATEGORY:

Guidance for Clinical Investigators, Institutional Review Boards, and Sponsors; Process for Handling Referrals to Food and Drug Administration Under 21 CFR 50.54: Additional Safeguards for Children in Clinical Investigations

DATES: General comments on agency guidance documents are welcome at any time.

DOCUMENT SUMMARY:

The Food and Drug Administration (FDA) is announcing the availability of a guidance entitled ``Guidance for Clinical Investigators, Institutional Review Boards, and Sponsors; Process for Handling Referrals to FDA Under 21 CFR 50.54: Additional Safeguards for Children in Clinical Investigations.'' This guidance is intended to assist clinical investigators, Institutional Review Boards (IRBs), sponsors, and other interested parties in understanding FDA's process for handling clinical investigations that include children as subjects and that
[[Page 77035]]
have been referred to FDA for review under FDA regulations on additional safeguards for children in clinical investigations. The guidance describes the procedures FDA generally intends to follow in handling clinical investigations referred for review under Sec. 50.54 (21 CFR 50.54) and in reaching final determinations in accordance with these regulations. The guidance announced in this notice finalizes the draft guidance of the same title dated May 2006.

SUMMARY:

Additional safeguards for children in clinical investigations; process for handling referrals to FDA,

SUPPLEMENTAL INFORMATION

I. Background

FDA is announcing the availability of a guidance entitled ``Guidance for Clinical Investigators, Institutional Review Boards, and Sponsors; Process for Handling Referrals to FDA Under 21 CFR 50.54: Additional Safeguards for Children in Clinical Investigations.'' FDA issued 21 CFR part 50, subpart D, ``Additional Safeguards for Children in Clinical Investigations,'' (subpart D) as an interim final rule on April 24, 2001 (66 FR 20598). Under these regulations, an IRB must review clinical investigations involving children as subjects and covered by subpart D and approve only those clinical investigations that satisfy the criteria described in Sec. Sec. 50.51, 50.52, or 50.53, as well as the conditions of all other applicable sections in subpart D.

Under Sec. 50.54, if an IRB does not believe that a clinical investigation within the scope described in Sec. Sec. 50.1 and 56.101 (21 CFR 56.101) and involving children as subjects meets the requirements of Sec. Sec. 50.51, 50.52, or 50.53, the clinical investigation may proceed only if:

  • (1) The IRB finds and documents that the clinical investigation presents a reasonable opportunity to further the understanding, prevention, or alleviation of a serious problem affecting the health or welfare of children; and
  • (2) The Commissioner of Food and Drugs, after consultation with a panel of experts in pertinent disciplines (for example: science, medicine, education, ethics, law) and following opportunity for public review and comment, determines either of the following:
  • That the clinical investigation in fact satisfies the conditions of Sec. 50.51, 50.52, or 50.53, as applicable, or
  • That the following conditions are met:
  • The clinical investigation presents a reasonable opportunity to further the understanding, prevention, or alleviation of a serious problem affecting the health or welfare of children;
  • The clinical investigation will be conducted in accordance with sound ethical principles; and
  • Adequate provisions are made for soliciting the assent of children and the permission of their parents or guardians as set forth in Sec. 50.55.

    The guidance describes the procedures FDA generally will follow in handling clinical investigations referred for review under Sec. 50.54 and in reaching final determinations under that regulation. The guidance is based in part on FDA's experience to date with such referrals. The Department of Health and Human Services (HHS) has human subject protection regulations that also govern research involving children as subjects and supported or conducted by HHS. (See 45 CFR part 46, subpart D.) The guidance also addresses situations in which a clinical investigation is subject to both 21 CFR 50.54 and 45 CFR 46.407.

    In the Federal Register of May 10, 2006 (71 FR 27264), FDA announced the availability of the draft guidance of the same title dated May 2006. FDA received a few comments on the draft guidance and those comments were considered as the guidance was finalized.

    This guidance is being issued consistent with FDA's good guidance practices regulation (21 CFR 10.115). The guidance represents the agency's current thinking on the process for handling referrals to FDA underSec. 50.54. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the requirements of the applicable statutes and regulations.

    II. The Paperwork Reduction Act of 1995

    This guidance refers to previously approved collections of information found in FDA regulations. These collections of information are subject to review by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (44 U.S.C. 35013520). The information required under Sec. 50.54 is a recordkeeping requirement. IRB recordkeeping requirements are set forth in FDA regulations on IRBs (21 CFR part 56) at Sec. 56.115. The collection of information in Sec. 56.115 has been approved under OMB Control No. 09100130. Although FDA had included an analysis of the estimated annual reporting burden in the notice of availability for the draft guidance (71 FR 27264), that analysis made clear that, based on the agency's experience to date with the regulation addressed in the guidance, FDA only expects approximately five respondents per year to submit information to the agency under the guidance. Accordingly, FDA has concluded that, under 5 CFR 1320.3(c), there is no collection of information associated with this guidance.

    III. Comments

    Interested persons may submit to the Division of Dockets Management (see ADDRESSES) written or electronic comments regarding this document. Submit a single copy of electronic comments or two paper copies of any mailed comments, except that individuals may submit one paper copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.

    IV. Electronic Access

    Persons with access to the Internet may obtain the document at either http://www.fda.gov/cber/guidelines.htm orhttp://www.fda.gov/ohrms/dockets/default.htm. /dockets/default.htm.

    Dated: December 15, 2006.
    Jeffrey Shuren,
    Assistant Commissioner for Policy.
    [FR Doc. E621950 Filed 122106; 8:45 am]
    BILLING CODE 416001S

    FOR FURTHER INFORMATION CONTACT

    Erik Mettler, Office of Policy (HF- 11), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 3018273360.

    • © 2009 theFederalRegister.com    Created by: Craig Wood | styleshout | Congressional Record        Home | RSS Feed